
Desmopressin (DDAVP) – Arabic
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may
Year: 2021
Language: Arabic
This resource is also available in: الإنجليزية الفرنسية الروسية الأسبانية
Format: Video
Listen to this 2-hour webinar presented on April 22, 2021 to learn about global topics related to bleeding disorders.
The session was moderated by Glenn Pierce (WFH Vice President, Medical) and Marlène Beijlevelt (WFH Nurses Committee chair).
Cedric Hermans (WFH Medical board member), Gianluigi Pasta (WFH MSK Committee chair), Sukesh Nair (Professor of laboratory haematology), Margareth Ozelo (Director of the Haematology Division, UNICAMP), Radoslaw Kaczmarek (WFH Coagulation Product Safety, Supply, and Access Committee chair) and John Pasi (Professor of Haemostasis and Thrombosis) presented practical information on bleeding disorders, such as what to cover in a 20-minute consult with a person with hemophilia (from both a clinical and musculoskeletal points of view), current lab issues and challenges, chromogenic assays, how bleeding disorder products are made, and what’s new with rebalancing agents.
This WFH webinar was originally presented in English.
To download a pdf of the slides of the webinar, click the icon below.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may

Also Available In: Japanese Access to a comprehensive hemophilia treatment centre (HTC) is a critical component of care. This fact

Also Available In: Japanese A national tender system is a cost-effective system for the purchase of products or services, such

Also Available In: Japanese Access to home treatment reduces the economic impact on healthcare systems and improves the quality of

Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic

Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia.